14 October 2024
EMA/452923/2024
EMEA/H/C/002630

Public statement

Memantine LEK (memantine hydrochloride)

Withdrawal of the marketing authorisation in the European Union

On 6 September 2024, the European Commission withdrew the marketing authorisation for Memantine LEK (memantine hydrochloride) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pharmathen S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Memantine LEK was granted marketing authorisation in the EU on 22 April 2013 for the treatment of Alzheimer's disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2018.

Memantine LEK is a generic medicine of Ebixa. There are other generic medicinal products of Ebixa authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Memantine LEK will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union